Anti Rat Podoplanin, Monoclonal Antibody (PMab-2)

Podoplanin, a single-transmembrane glycoprotein, has been known as a marker of lymphatic endothelium and alveolar epithelium. And also known to be overexpressed in brain tumor, malignant mesothelioma, testicular tumor, and various squamous cell carcinomas. Its expression is associated with a poor prognosis of some kinds of tumors.
Podoplanin has a highly conserved region, called PLAG domain, in its extracellular N-terminal region. In particular, podoplanin has been known to bind to CLEC-2, a receptor on the platelet, via PLAG3 domain sequence and sialylated O-glycan in PLAG3, inducing platelet aggregation. The platelet aggregation activity has been reported to be involved in metastatic and proliferation of cancer cells.

This is the first monoclonal antibody generated against rat podoplanin.
It recognizes the PLAG domain.

• Clone No.: PMab-2
• Source: Mouse
• Isotype: IgG1∙κ
• Antibody concentration: Approximately 1 mg/mL (indicated on the label)
• Cross-reactivity: Rat
• Specificity: Rat podoplanin
• Formulation: Liquid/PBS containing sodium azide.
• Application: Western blot (from 0.1 μg/mL)
  　　　　　　ELISA
  　　　　　　Flow cytometry (from 1 μg/mL)
  　　　　　　Immunohistochemistry (from 0.5 μg/mL)

※Please determine optimum experimental conditions for your application.

• Oki, H. et al., “Development of sensitive monoclonal antibody PMab-2 against rat podoplanin.”, Monoclon. Antib. Immunodiagn. Immunother., 34(6), 396-403 (2015).